コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ds resulted in deregulation of ecdysone- and farnesoid-regulated genes, accordingly with the observed
2 eticholic acid) is a potent activator of the farnesoid X nuclear receptor that reduces liver fat and
5 notype in SIRT mice correlated with impaired farnesoid X receptor (FXR) activity due to persistent de
6 eatment of mouse or human hepatocytes with a farnesoid X receptor (FXR) agonist GW4064 or bile acids
9 that GS can act as an antagonist ligand for farnesoid X receptor (FXR) and decrease expression of bi
10 bile acid-activated nuclear hormone receptor farnesoid X receptor (FXR) and G protein-coupled membran
12 in bile acid homeostasis with a focus on the farnesoid X receptor (FXR) and its potential therapeutic
13 metabolic homeostasis by activating nuclear farnesoid X receptor (Fxr) and membrane G-protein-couple
15 e rodent Sult2A1 gene is also induced by the farnesoid X receptor (FXR) and pregnane X receptor (PXR)
17 dback loop operated by the nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner
19 primarily regulated by the nuclear receptors farnesoid X receptor (FXR) and small heterodimer partner
20 id oxidation, and 3) decreased expression of farnesoid X receptor (FXR) and small heterodimer partner
21 Cholestasis activates bile acid receptor farnesoid X receptor (FXR) and subsequently enhances hep
22 key regulators of liver biology: C/EBPalpha, Farnesoid X Receptor (FXR) and telomere reverse transcri
23 that the fed-state sensing nuclear receptor farnesoid X receptor (FXR) and the fasting transcription
25 are ligands for the nuclear hormone receptor farnesoid X receptor (FXR) and the G protein-coupled rec
27 The bile acid-activated receptors, nuclear farnesoid X receptor (FXR) and the membrane Takeda G-pro
29 metabolism and inflammation via the nuclear farnesoid X receptor (FXR) and the Takeda G protein-coup
30 tor-activated receptor-alpha (PPARalpha) and farnesoid X receptor (FXR) are activated in the fasted a
33 This ERalpha binding site overlaps the known farnesoid X receptor (FXR) binding site in the SHP promo
35 the postprandial state, activation of ileal farnesoid X receptor (FXR) by bile salts results in tran
36 contribute to steatosis induced by diet and farnesoid X receptor (FXR) deficiency in both genders.
37 ether fibroblast growth factor 19 (FGF19) or farnesoid X receptor (FXR) dependent signaling are invol
41 emic expression of the bile acid (BA) sensor farnesoid X receptor (FXR) has led to promising new ther
42 ontrast to mice, human BSEP was regulated by farnesoid X receptor (FXR) in an isoform-dependent manne
44 CYP7A1 transcription by bile acid-activated farnesoid X receptor (FXR) in its native promoter and ce
46 nd synthetic (i.e. GW4064) activators of the farnesoid X receptor (FXR) increased FGF21 gene expressi
48 e report that the nuclear bile acid receptor farnesoid X receptor (FXR) inhibits microRNA-34a (miR-34
64 ation of bile acid synthesis mediated by the farnesoid X receptor (FXR) is disrupted in the mutant mi
65 igand activated transcription factor nuclear farnesoid X receptor (FXR) is involved as a regulator in
68 s were performed with islets from wild-type, farnesoid X receptor (FXR) knockout (KO), and beta-cell
71 dy, we show that LPS significantly decreases farnesoid X receptor (FXR) mRNA in mouse liver as early
74 cholestasis by altering the activity of the farnesoid X receptor (FXR) or by impairing the structure
84 xamined, and expression of genes involved in farnesoid X receptor (FXR) signaling in the liver and in
89 ctivate small heterodimer partner (SHP) upon farnesoid X receptor (FXR) stimulation by increasing BA
90 re we report that Foxm1b is the first direct farnesoid X receptor (FXR) target gene known to be invol
91 that the MDR3 gene is trans-activated by the farnesoid X receptor (FXR) via a direct binding of FXR/r
92 given an intracerebroventricular infusion of farnesoid X receptor (FXR) Vivo-morpholino before AOM in
94 Our previous studies have shown that the farnesoid X receptor (FXR), a bile acid-activated nuclea
95 is and mutations in NR1H4, which encodes the farnesoid X receptor (FXR), a bile acid-activated nuclea
97 signal through two major receptor pathways: farnesoid X receptor (FXR), a member of the nuclear horm
98 ne is a highly efficacious antagonist of the farnesoid X receptor (FXR), a nuclear hormone receptor t
100 is strongly up-regulated by agonists of the farnesoid X receptor (FXR), a nuclear receptor for bile
101 and-binding domain (LBD) of human and murine farnesoid X receptor (FXR), a nuclear receptor for bile
102 t studies to serve as a binding site for the farnesoid X receptor (FXR), a nuclear receptor for bile
103 n of hepatic SIRT1 reduces the expression of farnesoid X receptor (FXR), a nuclear receptor that regu
104 is mediated through the bile acid-activated farnesoid X receptor (FXR), a recently characterized mem
105 bile acids are physiological ligands for the farnesoid X receptor (FXR), an orphan nuclear receptor.
106 sodium-dependent bile acid transporter, the farnesoid X receptor (FXR), and familial intrahepatic ch
109 luding those of nuclear receptors, primarily farnesoid X receptor (FXR), membrane BA receptors, and F
110 mice with intestine-specific knockout of the farnesoid X receptor (FXR), mice that express an FXR tra
111 Enterohepatic nuclear receptors including farnesoid X receptor (FXR), pregnane X receptor (PXR), a
112 Geniposide also down-regulated expression of Farnesoid X receptor (FXR), small heterodimer partner (S
115 holesterol, liver X receptors (LXRs) and the farnesoid X receptor (FXR), together with other members
116 n of BSEP gene expression is mediated by the farnesoid X receptor (FXR), which binds as a heterodimer
118 ntagonist ligands for the bile acid receptor farnesoid X receptor (FXR), which is an important regula
119 al and transactivational regulator of murine farnesoid X receptor (Fxr), which is the primary bile ac
121 gulates triglyceride metabolism through both farnesoid X receptor (FXR)-dependent and -independent pa
122 Cholate treatment was associated with a farnesoid X receptor (FXR)-dependent increase in hepatic
123 ntracellular bile acids results in repressed farnesoid X receptor (FXR)-FGF15 signalling, leading to
124 pact of sulfated progesterone metabolites on farnesoid X receptor (FXR)-mediated bile acid homeostasi
139 r receptors PPARalpha (encoded by NR1C1) and farnesoid X receptor (FXR, encoded by NR1H4) are activat
144 ation of the nuclear and membrane receptors, farnesoid X receptor (FXR-alpha) and TGR5 (G-protein-cou
149 lic acid, and deoxycholic acid activated the farnesoid X receptor (FXR; NR1H4), an orphan nuclear rec
150 he decreased sensitivity of mice lacking the farnesoid X receptor (FXR; nuclear receptor subfamily 1,
151 1, higher Srepb2 messenger RNA (mRNA), lower farnesoid X receptor (Nr1h4) mRNA, and lower Cyp7a1 mRNA
152 eptor subfamily 1 group H member 4 (NR1H4 or farnesoid X receptor [FXR]) regulates bile acid synthesi
156 s of BS synthesis-suppressing drugs, such as farnesoid X receptor agonists, is greatest when optimal
157 ated receptor alpha (PPARalpha) and RXRalpha/farnesoid X receptor alpha (FXRalpha) heterodimeric nucl
158 ed receptor alpha (PPARalpha), RXRalpha plus farnesoid X receptor alpha (FXRalpha), liver receptor ho
159 n, it appears that retinoid X receptor alpha/farnesoid X receptor alpha and liver receptor homolog 1
160 pathway inhibition induced the expression of farnesoid X receptor alpha, a transcription factor that
162 s, has been recently shown to antagonize the farnesoid X receptor and decrease the expression of bile
163 lase most likely resulted from activation of farnesoid X receptor and induction of fibroblast growth
164 the orchestrated regulation mediated by the farnesoid X receptor and small heterodimer partner that
166 dulation of bile acid receptors, such as the farnesoid X receptor and TGR5, and transporters, such as
167 drug targets include the bile BA receptors, farnesoid X receptor and TGR5, the BA-induced gut hormon
169 imetastatic effects of guggulsterone (GS), a farnesoid X receptor antagonist, are linked to its abili
171 rol saturation index, a 2.5-fold increase in farnesoid X receptor expression, a 5-fold increase in LX
173 is mediated through the retinoid X receptor/farnesoid X receptor heterodimer and is independent of b
174 nd suggest that pharmacological targeting of farnesoid X receptor in vivo can be used to reverse the
178 ulation of ASBT by bile acids is mediated by farnesoid X receptor via small heterodimer partner-depen
181 ry activities of the hepatic TR, NR1H4 (FXR; farnesoid X receptor), as our model system to tackle thi
182 ptors, particularly the primary BA receptor, farnesoid X receptor, and small heterodimer partner, whi
184 d nuclear receptors (i.e., liver X receptor, farnesoid X receptor, estrogen receptor alpha, peroxisom
185 of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreas
186 1 (LSD1) is directly induced by BA-activated farnesoid X receptor, is recruited to the BA synthetic g
187 p7b1, and produces partial resistance to the farnesoid X receptor, leading to a lithogenic bile salt
188 d B6J mice, including the bile acid receptor farnesoid X receptor, oxysterol 7alpha-hydroxylase, ster
189 ty to modulate bile acid activated proteins: farnesoid X receptor, vitamin D receptor, pregnane X rec
190 deoxycholic acid, the natural agonist of the farnesoid X receptor, which is a nuclear hormone recepto
191 anscription of the gene (Nr1h4) encoding the farnesoid X receptor-1 (Fxr-1), thereby leading to reduc
193 pd3 expression was attenuated in LCA-treated farnesoid X receptor-null mice that are resistant to LCA
203 receptor (LXR)/retinoid X receptor (RXR) and farnesoid X receptor/RXR nuclear receptor signaling amon
205 me proliferator-activated receptors (PPARs), farnesoid X receptors (FXRs), liver X receptors (LXRs),
206 ated receptor (clofibrate or linoleic acid), farnesoid X-activated receptor (farnesol or juvenile hor
207 xpressed in human livers and is regulated by farnesoid X-activated receptor (FXR) in response to FXR
209 tamins and are physiological ligands for the farnesoid X-activated receptor (FXR), a member of the nu
210 iferator activated receptors (PPARs) and the farnesoid X-activated receptor (FXR), on the development
213 e proliferator-activated receptor and of the farnesoid X-activated receptor accelerate epidermal barr
214 or-alpha ligand, and juvenile hormone III, a farnesoid X-activated receptor activator, markedly accel
215 eroxisome proliferator-activated receptor or farnesoid X-activated receptor activators, or by an acti
216 eroxisome proliferator-activated receptor or farnesoid X-activated receptor are involved in this gluc
218 that the class II nuclear hormone receptor, farnesoid X-receptor (FXR), incorporates histone methylt
219 and transfected with expression plasmids for farnesoid X-receptor (FXR), short heterodimer partner (S
222 t that overexpression of a dominant-negative farnesoid X-receptor eliminated the bile acid mediated d
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。